NovoCure Limited
NVCR
Jodie situation report
NovoCure Limited's current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 13 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 5 directly disclosed connections are confirming.
- NVCR's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if NVCR's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind NVCR
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
Depended on by
ZLABZai Lab LimitedpartnerAug 7, 2025 ▾
“Tumor Treating Fields (TTFields): In May 2025, our partner NovoCure presented results from the Phase III PANOVA-3 trial of TTFields therapy for pancreatic cancer at the 2025 ASCO Annual Meeting and simultaneously published in the Journal of Clinical Oncology.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 2 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
NVCR is currently a Follower in the organic co-movement group Regional Financial Services. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for NVCR; it is not active in the latest market snapshot.